Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated with the rapid rise in insulin resistance, obesity, and diabetes prevalence, making it one of the most common chronic liver diseases worldwide. Fatty liver can lead to systemic metabolic dysfunction and further progress to steatohepatitis, hepatic fibrosis, cirrhosis, and even hepatocellular carcinoma. However, current clinical interventions are limited to lifestyle and dietary modifications, with no effective drugs or therapies available for MASLD. Hepatic lipid metabolism dysregulation, caused by an imbalance between lipid acquisition and utilization, is a primary driver of MASLD, with fatty acid uptake being a critical step facilitated by…